Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene

References

• PolitiMCSchleinitzMDColNFRevisiting the duration of vasomotor symptoms of menopause: a meta-analysisJ Gen Intern Med20082391507151318521690
   PubMed Web of Science ®Google Scholar
• WilliamsREKalilaniLDiBenedettiDBFrequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United StatesClimacteric2008111324318202963
   PubMed Web of Science ®Google Scholar
• NappiREKokot-KierepaMVaginal health: insights, views & attitudes (VIVA) – results from an international surveyClimacteric2012151364422168244
   PubMed Web of Science ®Google Scholar
• FreemanEWSammelMDSandersRJRisk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohortMenopause201421992493224473530
   PubMed Web of Science ®Google Scholar
• GartoullaPWorsleyRBellRJDavisSRModerate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 yearsMenopause201522769470125706184
   PubMed Web of Science ®Google Scholar
• HemminkiERegushevskayaELuotoRVeerusPVariability of bothersome menopausal symptoms over time – a longitudinal analysis using the Estonian postmenopausal hormone therapy trial (EPHT)BMC Womens Health2012124423259658
   PubMed Web of Science ®Google Scholar
• GBD 2013 Mortality and Causes of Death CollaboratorsGlobal, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013Lancet2015385996311717125530442
   PubMed Web of Science ®Google Scholar
• AvisNECrawfordSLGreendaleGStudy of Women’s Health Across the NationDuration of menopausal vasomotor symptoms over the menopause transitionJAMA Intern Med2015175453153925686030
   PubMed Web of Science ®Google Scholar
• The North American Menopause SocietyThe 2012 hormone therapy position statement of The North American Menopause SocietyMenopause201219325727122367731
   PubMed Web of Science ®Google Scholar
• StuenkelCAGassMLMansonJEA decade after the Women’s Health Initiative – the experts do agreeMenopause201219884684722776849
   PubMed Web of Science ®Google Scholar
• ShifrenJLGassMLThe North American Menopause Society recommendations for clinical care of midlife womenMenopause201421101038106225225714
   PubMed Web of Science ®Google Scholar
• de VilliersTJGassMLHainesCJGlobal consensus statement on menopausal hormone therapyClimacteric201316220320423488524
   PubMed Web of Science ®Google Scholar
• de VilliersTJPinesAPanayNInternational Menopause SocietyUpdated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife healthClimacteric201316331633723672656
   PubMed Web of Science ®Google Scholar
• Neves-E-CastroMBirkhauserMSamsioeGEMAS position statement: the ten point guide to the integral management of menopausal healthMaturitas2015811889225757366
   PubMed Web of Science ®Google Scholar
• KaunitzAMExtended duration use of menopausal hormone therapyMenopause201421667968124398408
   PubMed Web of Science ®Google Scholar
• North American Menopause Society [webpage on the Internet]The North American Menopause Society statement on continuing use of systemic hormone therapy after age 65North American Menopause Society [updated 2015]. Available from: http://www.menopause.org/docs/default-source/2015/2015-nams-hormone-therapy-after-age-65.pdfAccessed June 9, 2015
   Google Scholar
• AndersonGLLimacherMAssafARWomen’s Health Initiative Steering CommitteeEffects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trialJAMA2004291141701171215082697
   PubMed Web of Science ®Google Scholar
• RossouwJEAndersonGLPrenticeRLWriting Group for the Women’s Health Initiative InvestigatorsRisks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trialJAMA2002288332133312117397
   PubMed Web of Science ®Google Scholar
• MansonJEChlebowskiRTStefanickMLMenopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trialsJAMA2013310131353136824084921
   PubMed Web of Science ®Google Scholar
• HaysJOckeneJKBrunnerRLWomen’s Health Initiative InvestigatorsEffects of estrogen plus progestin on health-related quality of lifeN Engl J Med2003348191839185412642637
   PubMed Web of Science ®Google Scholar
• ChlebowskiRTHendrixSLLangerRDWHI InvestigatorsInfluence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trialJAMA2003289243243325312824205
   PubMed Web of Science ®Google Scholar
• ChlebowskiRTAndersonGLGassMWHI InvestigatorsEstrogen plus progestin and breast cancer incidence and mortality in postmenopausal womenJAMA2010304151684169220959578
   PubMed Web of Science ®Google Scholar
• AndersonGLChlebowskiRTAragakiAKConjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trialLancet Oncol201213547648622401913
   PubMed Web of Science ®Google Scholar
• BarnabeiVMCochraneBBAragakiAKWomen’s Health Initiative InvestigatorsMenopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health InitiativeObstet Gynecol20051055 pt 11063107315863546
   PubMed Web of Science ®Google Scholar
• ReganMMEmondSKAttardoMJParkerRAGreenspanSLWhy do older women discontinue hormone replacement therapy?J Womens Health Gend Based Med200110434335011445025
   PubMedGoogle Scholar
• AmeyeLAntoineCPaesmansMde AzambujaERozenbergSMenopausal hormone therapy use in 17 European countries during the last decadeMaturitas201479328729125156453
   PubMed Web of Science ®Google Scholar
• SpragueBLTrentham-DietzACroninKAA sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010Obstet Gynecol2012120359560322914469
   PubMed Web of Science ®Google Scholar
• Lohr A. [webpage on the Internet]First of its kind “menopause map” helps women navigate treatment [updated 2015] Available from: https://www.endocrine.org/news-room/press-release-archives/2012/first-of-its-kind-menopause-map-helps-women-navigate-treatmentAccessed July 2, 2015
   Google Scholar
• SarrelPPortmanDLefebvrePIncremental direct and indirect costs of untreated vasomotor symptomsMenopause201522326026625714236
   PubMed Web of Science ®Google Scholar
• UtianWHPsychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive reviewHealth Qual Life Outcomes200534716083502
   PubMedGoogle Scholar
• GartoullaPBellRJWorsleyRDavisSRModerate-severely bothersome vasomotor symptoms are associated with lowered psychological general wellbeing in women at midlifeMaturitas201581448749226115590
   PubMed Web of Science ®Google Scholar
• SimonJANappiREKingsbergSAMaamariRBrownVClarifying vaginal atrophy’s impact on sex and relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partnersMenopause201421213714223736862
   PubMed Web of Science ®Google Scholar
• SimonJAKokot-KierepaMGoldsteinJNappiREVaginal health in the United States: results from the vaginal health: insights, views & attitudes surveyMenopause201320101043104823571518
   PubMed Web of Science ®Google Scholar
• PinkertonJVSantoroNCompounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US womenMenopause201522992693625692877
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. [webpage on the Internet]Committee opinion 532: compounded bioidentical menopausal hormone therapy [updated August, 2012]. Available from: http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Compounded-Bioidentical-Menopausal-Hormone-TherapyAccessed August 21, 2014
   Google Scholar
• RossouwJEPrenticeRLMansonJEPostmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopauseJAMA2007297131465147717405972
   PubMed Web of Science ®Google Scholar
• The North American Menopause SocietyManagement of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause SocietyMenopause201320988890223985562
   PubMed Web of Science ®Google Scholar
• GoodmanMPAre all estrogens created equal? A review of oral vs. transdermal therapyJ Womens Health (Larchmt)201221216116922011208
   PubMed Web of Science ®Google Scholar
• FilesJAMillerVMChaSSPruthiSEffects of different hormone therapies on breast pain in recently postmenopausal women: findings from the Mayo Clinic KEEPS breast pain ancillary studyJ Womens Health (Larchmt)2014231080180525268853
   PubMed Web of Science ®Google Scholar
• KlingJMLahrBABaileyKRHarmanSMMillerVMMulvaghSLEndothelial function in women of the Kronos Early Estrogen Prevention StudyClimacteric201518218719725417709
   PubMed Web of Science ®Google Scholar
• MillerVMLahrBDBaileyKRHeitJAHarmanSMJayachandranMLongitudinal effects of menopausal hormone treatments on platelet characteristics and cell-derived microvesiclesPlatelets2015 Epub201549
   Web of Science ®Google Scholar
• Osphena [package insert]Florham Park, NJShionogi Inc.2015
   Google Scholar
• BachmannGAKomiJOOspemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 studyMenopause201017348048620032798
   PubMed Web of Science ®Google Scholar
• PortmanDJBachmannGASimonJAOspemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophyMenopause201320662363023361170
   PubMed Web of Science ®Google Scholar
• PortmanDJGassMLGenitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause SocietyMenopause201421101063106825160739
   PubMed Web of Science ®Google Scholar
• SimonJALinVHRadovichCBachmannGAOne-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterusMenopause201320441842723096251
   PubMed Web of Science ®Google Scholar
• McClungMRSirisECummingsSPrevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifeneMenopause200613337738616735934
   PubMed Web of Science ®Google Scholar
• FisherBCostantinoJPWickerhamDLTamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJ Natl Cancer Inst19989018137113889747868
   PubMed Web of Science ®Google Scholar
• ChristiansenCChesnutCH3rdAdachiJDSafety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosisBMC Musculoskelet Disord20101113020569451
   PubMed Web of Science ®Google Scholar
• Brisdelle [package insert]Miami, FLNoven Therapeutics, LLC2013
   Google Scholar
• SimonJAPortmanDJKaunitzAMLow-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trialsMenopause201320101027103524045678
   PubMed Web of Science ®Google Scholar
• PortmanDJKaunitzAMKazempourKMekonnenHBhaskarSLippmanJEffects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopauseMenopause201421101082109024552977
   PubMed Web of Science ®Google Scholar
• PinkertonJVArcherDFGuico-PabiaCJHwangEChengRFMaintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trialMenopause2013201384623266839
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [webpage on the Internet]Estradiol vaginal softgel capsules in treating symptoms of vulvar and vaginal atrophy in postmenopausal women (REJOICE) NCT02253173ClinicalTrials.gov [updated April 28, 2015]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02253173Accessed June 9, 2015
   Google Scholar
• MirkinSAmadioJMBernickBAPickarJHArcherDF17beta-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence reviewMaturitas2015811283525835751
   PubMed Web of Science ®Google Scholar
• PickarJHBonCAmadioJMMirkinSBernickBPharmacokinetics of the first combination 17beta-estradiol/progesterone capsule in clinical development for menopausal hormone therapyMenopause201522121308131625944519
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [webpage on the Internet]A safety and efficacy study of the combination estradiol and progesterone to treat vasomotor symptoms (REPLENISH) NCT01942668ClinicalTrials.gov [updated May 5, 2015]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01942668?term=REPLENISH&rank=1Accessed June 9, 2015
   Google Scholar
• FreemanEWGuthrieKACaanBEfficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trialJAMA2011305326727421245182
   PubMed Web of Science ®Google Scholar
• GordonPRKerwinJPBoesenKGSenfJSertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general populationMenopause200613456857516837878
   PubMed Web of Science ®Google Scholar
• JoffeHGuthrieKALaCroixAZLow-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trialJAMA Intern Med201417471058106624861828
   PubMed Web of Science ®Google Scholar
• PinkertonJVKaganRPortmanDSathyanarayanaRSweeneyMPhase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopauseMenopause201421656757324149930
   PubMed Web of Science ®Google Scholar
• KharodeYBodinePVMillerCPLyttleCRKommBSThe pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis preventionEndocrinology2008149126084609118703623
   PubMed Web of Science ®Google Scholar
• KommBSMirkinSJenkinsSNDevelopment of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone lossSteroids201490718124929044
   PubMed Web of Science ®Google Scholar
• SweetlandSBeralVBalkwillAMillion Women Study CollaboratorsVenous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective studyJ Thromb Haemost2012102277228622963114
   PubMed Web of Science ®Google Scholar
• SmithNLBlondonMWigginsKLLower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogensJAMA Intern Med20141741253124081194
   PubMed Web of Science ®Google Scholar
• ShufeltCLMerzCNPrenticeRLHormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women’s Health Initiative Observational StudyMenopause201421326026624045672
   PubMed Web of Science ®Google Scholar
• EthunKFWoodCEClineJMRegisterTCApptSEClarksonTBEndometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate modelMenopause201320777778423793168
   PubMed Web of Science ®Google Scholar
• EthunKFWoodCERegisterTCClineJMApptSEClarksonTBEffects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeysMenopause201219111242125223103754
   PubMed Web of Science ®Google Scholar
• KulakJJrFischerCKommBTaylorHSTreatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse modelEndocrinology201115283226323221586552
   PubMed Web of Science ®Google Scholar
• Lewis-WambiJSKimHCurpanRGriggRSarkerMAJordanVCThe selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1Mol Pharmacol201180461062021737572
   PubMed Web of Science ®Google Scholar
• WardellSENelsonERChaoCAMcDonnellDPBazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced diseaseClin Cancer Res20131992420243123536434
   PubMed Web of Science ®Google Scholar
• PeanoBJCrabtreeJSKommBSWinnekerRCHarrisHAEffects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary glandEndocrinology200915041897190319022889
   PubMed Web of Science ®Google Scholar
• ChangKCWangYBodinePVNagpalSKommBSGene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogensJ Steroid Biochem Mol Biol20101181–211712419914376
   PubMed Web of Science ®Google Scholar
• SongYSantenRJWangJPYueWInhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitroEndocrinology2013154265666523254198
   PubMed Web of Science ®Google Scholar
• StovallDWUtianWHGassMLThe effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safetyMenopause2007143 pt 151051717314736
   PubMed Web of Science ®Google Scholar
• Van DurenDRonkinSPickarJConstantineGBazedoxifene combined with conjugated estrogens: a novel alternative to traditional hormone therapies [abstract O-206]Fertil Steril2006863 supplS88S89
   Web of Science ®Google Scholar
• PickarJHYehITBachmannGSperoffLEndometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapyFertil Steril20099231018102419635613
   PubMed Web of Science ®Google Scholar
• LoboRAPinkertonJVGassMLEvaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profileFertil Steril20099231025103819635615
   PubMed Web of Science ®Google Scholar
• PinkertonJVUtianWHConstantineGDOlivierSPickarJHRelief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trialMenopause20091661116112419546826
   PubMed Web of Science ®Google Scholar
• FreemanEWEnsrudKELarsonJCPlacebo improvement in pharmacologic treatment of menopausal hot flashes: time course, duration, and predictorsPsychosom Med201577216717525647753
   PubMed Web of Science ®Google Scholar
• PinkertonJVAbrahamLBushmakinAGEvaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause, And Response to Therapy (SMART) trialsJ Womens Health (Larchmt)2014231182824206058
   PubMed Web of Science ®Google Scholar
• LindsayRGallagherJCKaganRPickarJHConstantineGEfficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal womenFertil Steril20099231045105219635616
   PubMed Web of Science ®Google Scholar
• MirkinSKommBSPanKChinesAAEffects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal womenClimacteric201316333834623038989
   PubMed Web of Science ®Google Scholar
• PinkertonJVHarveyJALindsayRSMART-5 InvestigatorsEffects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trialJ Clin Endocrinol Metab2014992E189E19824438370
   PubMed Web of Science ®Google Scholar
• KaganRWilliamsRSPanKMirkinSPickarJHA randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal womenMenopause201017228128919779382
   PubMed Web of Science ®Google Scholar
• BachmannGBobulaJMirkinSEffects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophyClimacteric201013213214019863455
   PubMed Web of Science ®Google Scholar
• Guidance for Industry [webpage on the Internet]Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms – recommendaitons for clinical evaluationFood and Drug Administration [updated January, 2003]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory-information/guidances/ucm071643.pdfAccessed January 6, 2014
   Google Scholar
• European Medicines Agency [webpage on the Internet]Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal womenEuropean Medicines Agency [updated May 1, 2006]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003348.pdfAccessed May 19, 2014
   Google Scholar
• KulakJJrFerrianiRAKommBSTaylorHSTissue selective estrogen complexes (TSECs) differentially modulate markers of proliferation and differentiation in endometrial cellsReprod Sci201320212913723171676
   PubMed Web of Science ®Google Scholar
• ClarkeCLSutherlandRLProgestin regulation of cellular proliferationEndocr Rev19901122663012114281
   PubMed Web of Science ®Google Scholar
• MirkinSPinkertonJVKaganRGynecologic safety of conjugated estrogens plus bazedoxifene: pooled analysis of 5 phase 3 trialsJ Womens Health Accepted for publication
   Web of Science ®Google Scholar
• PalaciosSSilvermanSLde VilliersTJBazedoxifene Study GroupA 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fractureMenopause201522880681325668306
   PubMed Web of Science ®Google Scholar
• HarveyJAPinkertonJVBaracatECShiHChinesAAMirkinSBreast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogensMenopause201320213814523271189
   PubMed Web of Science ®Google Scholar
• PinkertonJVHarveyJAPanKBreast effects of bazedoxifene-conjugated estrogens: a randomized controlled trialObstet Gynecol2013121595996823635731
   PubMed Web of Science ®Google Scholar
• CrandallCJAragakiAKCauleyJABreast tenderness after initiation of conjugated equine estrogens and mammographic density changeBreast Cancer Res Treat2012131396997921979747
   PubMed Web of Science ®Google Scholar
• AssiVMassatNJThomasSA case-control study to assess the impact of mammographic density on breast cancer risk in women aged 40–49 at intermediate familial riskInt J Cancer2015136102378238725333209
   PubMed Web of Science ®Google Scholar
• BoydNFLockwoodGAByngJWTritchlerDLYaffeMJMammographic densities and breast cancer riskCancer Epidemiol Biomarkers Prev1998712113311449865433
   PubMed Web of Science ®Google Scholar
• CarneyPAMigliorettiDLYankaskasBCIndividual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammographyAnn Intern Med2003138316817512558355
   PubMed Web of Science ®Google Scholar
• PalaciosSde VilliersTJNardoneFCBZA Study GroupAssessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 studyMaturitas2013761818723871271
   PubMed Web of Science ®Google Scholar
• KommBSThompsonJRMirkinSCardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trialsClimacteric201518119
   Web of Science ®Google Scholar
• CurbJDPrenticeRLBrayPFVenous thrombosis and conjugated equine estrogen in women without a uterusArch Intern Med2006166777278016606815
   PubMedGoogle Scholar
• MirkinSPanKRyanKAChinesAStevensonJCA pooled analysis of the effects of conjugated estrogens/bazedoxifene on lipid parameters in postmenopausal women from the Selective estrogens, Menopause, And Response to Therapy (SMART) trialsJ Clin Endocrinol Metab201510062329233825894963
   PubMed Web of Science ®Google Scholar
• ArcherDFLewisVCarrBROlivierSPickarJHBazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal womenFertil Steril20099231039104419635614
   PubMed Web of Science ®Google Scholar
• GoldsteinSRKaganRIncidence of bleeding or spotting with a conjugated estrogen/bazedoxifene compound compared to conjugated estrogen/progestogen to placeboPoster P-31 Presented at: Annual Meeting of the North American Menopause SocietySeptember 30–October 3, 2015Las Vegas, NV.
   Google Scholar
• CrandallCJAragakiAKCauleyJABreast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone Women’s Health Initiative clinical trialsBreast Cancer Res Treat2012132127528522042371
   PubMed Web of Science ®Google Scholar
• GirdlerSSO’BriantCSteegeJGrewenKLightKCA comparison of the effect of estrogen with or without progesterone on mood and physical symptoms in postmenopausal womenJ Womens Health Gend Based Med19998563764610839650
   PubMedGoogle Scholar
• JungSJShinAKangDHormone-related factors and post-menopausal onset depression: results from KNHANES (2010–2012)J Affect Disord201517517618325622021
   PubMed Web of Science ®Google Scholar
• GleasonCEDowlingNMWhartonWEffects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective studyPLoS Med2015126e100183326035291
   PubMed Web of Science ®Google Scholar
• SitesCKL’HommedieuGDTothMJBrochuMCooperBCFairhurstPAThe effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trialJ Clin Endocrinol Metab20059052701270715687338
   PubMed Web of Science ®Google Scholar
• GodslandIFGangarKWaltonCInsulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapyMetabolism19934278468538345794
   PubMed Web of Science ®Google Scholar
• ShadoanMKKavanaghKZhangLAnthonyMSWagnerJDAddition of medroxyprogesterone acetate to conjugated equine estrogens results in insulin resistance in adipose tissueMetabolism200756683083717512317
   PubMed Web of Science ®Google Scholar
• SpencerCPGodslandIFCooperAJRossDWhiteheadMIStevensonJCEffects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal womenMetabolism200049674274710877199
   PubMed Web of Science ®Google Scholar
• AbrahamLPinkertonJVMessigMRyanKAKommBSMirkinSMenopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifeneMaturitas201478321221824837362
   PubMed Web of Science ®Google Scholar
• UtianWYuHBobulaJMirkinSOlivierSPickarJHBazedoxifene/conjugated estrogens and quality of life in postmenopausal womenMaturitas200963432933519647382
   PubMed Web of Science ®Google Scholar
• PinkertonJVPanKAbrahamLSleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trialMenopause201421325225923942245
   PubMed Web of Science ®Google Scholar
• PinkertonJVBushmakinAGRacketaJCappelleriJCChinesAAMirkinSEvaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modelingMenopause201421324325123899830
   PubMed Web of Science ®Google Scholar
• TansupswatdikulPChaikittisilpaSJaimchariyatamNPanyakhamlerdKJaisamrarnUTaechakraichanaNEffects of estrogen therapy on postmenopausal sleep quality regardless of vasomotor symptoms: a randomized trialClimacteric201518219820425242569
   PubMed Web of Science ®Google Scholar